Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
- Pathologically confirmed MPNST, with or without underlying diagnosis of neurofibromatosis type 1 (diagnostic criteria for neurofibromatosis type 1)
- Measurable disease as defined by at least one tumor that is measurable in two dimensions on CT or magnetic resonance imaging (MRI) scan (minimum size 1.0 cm for at least one lesion)
- MPNST for which standard therapy is not curative, including patients with surgically unresectable lesions, progression (WHO criteria) or recurrence of an MPNST in a previously radiated field (if it has been at least 4 weeks prior to registration since the last dose of radiation); Note: patients with metastatic disease also are eligible for participation
- Patient may have more than one site of recurrent or metastatic disease but only one lesion that is >= 1 cm in size will be injected (if in the lung, the lesion must be >= 2 cm and adjacent to the pleura in the lung)
- Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500
- Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000
- Obtained =< 14 days prior to registration: Hemoglobin (HgB) >= 9.0 g/dL
- Obtained =< 14 days prior to registration: Total bilirubin =< institutional upper limit of normal (ULN)
- Obtained =< 14 days prior to registration: Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 1.5 x upper limit of normal (ULN)
- Obtained =< 14 days prior to registration: Creatinine =< 1.0 mg/dL
- Obtained =< 14 days prior to registration: International normalized ratio (INR) =< 2.0
- Negative pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
- Provide informed written consent
- Willingness to return to Mayo Clinic Rochester for follow-up
- Willingness to provide biologic samples for correlative research purposes
- Life expectancy >= 12 weeks
- Cluster of differentiation (CD)4 count >= 200/uL or >= 15% of peripheral blood lymphocytes
- Ability to complete questionnaire(s) by themselves or with assistance
- Any of the following * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of treatment
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Receiving therapeutic anticoagulation (Coumadin or low molecular weight heparin, heparin, apixaban, dabigatran, rivaroxaban, warfarin)
- Active infection =< 5 days prior to registration
- History of tuberculosis or history of purified protein derivative (PPD) positivity
- Any of the following prior therapies: * Chemotherapy =< 3 weeks prior to registration * Immunotherapy =< 4 weeks prior to registration * Biologic therapy =< 4 weeks prior to registration * Radiation therapy =< 3 weeks prior to registration
- Failure to fully recover from acute, reversible effects defined as =< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4.0 of prior chemotherapy regardless of interval since last treatment except alopecia and neuropathy
- Requiring blood product support
- Patient has central nervous system (CNS) metastases or seizure disorder
- Human immunodeficiency virus (HIV)-positive test result or history of other immunodeficiency
- History of organ transplantation
- History of chronic hepatitis B or C
- Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)
- Treatment with oral/systemic corticosteroids, with the exception of topical or inhaled steroids
- Current exposure to household contacts =< 15 months old or household contact with known immunodeficiency; NOTE: patient must avoid contact during documented viral shedding; participants with continuous viral shedding will be given recommendations for restricted activities to avoid contact with immunocompromised persons
- Allergy to measles vaccine or history of severe reaction to prior measles vaccination
- Allergy to iodine; Note: this does not include reactions to intravenous contrast materials
- Allergy to lidocaine, fentanyl, midazolam, or propofol (may be used during tumor biopsy or injection)
I. To determine the maximum tolerated dose (MTD) of intratumoral administration of an Edmonston strain measles virus genetically engineered to express neurofibromatosis type 1 (NIS) (oncolytic measles virus encoding thyroidal sodium iodide symporter [MV-NIS]) in patients with inoperable or recurrent malignant peripheral nerve sheath tumor (MPNST).
II. To determine the safety and toxicity of intratumoral administration of MV-NIS in patients with inoperable recurrent MPNST.
III. To preliminarily assess antitumor efficacy of intratumoral MV-NIS administration by the rate of progression-free survival at 3 months, achieved by following radiographic response of the treated lesion using World Health Organization (WHO) response criteria guidelines.
I. To determine the time course of viral gene expression and virus elimination and biodistribution of virally infected cells at various time points after infection with MV-NIS using single-photon emission computed tomography (SPECT)/computed tomography (CT) imaging.
II. To assess viremia, viral replication, and measles virus shedding/persistence following intratumoral administration.
III. To determine humoral and cellular immune response to the injected virus.
IV. To assess the quality-of-life of patients treated with MV-NIS, using two inventories (Pain and Fatigue).
V. To assess time to progression and differences in growth rates between treated and untreated tumor lesions.
VI. To assess the overall survival time of patients treated with MV-NIS.
Patients receive MV-NIS intratumorally on day 1. Patients also undergo SPECT/CT at baseline and at 3 and 8 days after MV-NIS. Patients may also undergo SPECT/CT at 15 and 28 days, and at 6 weeks based on whether there is uptake on prior imaging studies.
After completion of study treatment, patients are followed up at 3, 6, 12, 18, and 24 months.
Trial Phase Phase I
Trial Type Treatment
Mayo Clinic in Rochester
- Primary ID MC1372
- Secondary IDs NCI-2016-00179
- Clinicaltrials.gov ID NCT02700230